Myxoma Virus Expressing a Fusion Protein of Interleukin-15 (IL15) and IL15 Receptor Alpha Has Enhanced Antitumor Activity
Figure 8
Prolonged survival of C57BL/6 mice bearing subcutaneous B16-F10 tumors treated with vMyx-IL15Rα-tdTr intratumorally.
C57BL/6 mice (5 mice per group) were implanted with subcutaneous B16-F10 tumor cells. 7 days later, when tumors reached approximately 100 mm3, virus was inoculated intratumorally (i.t.) with 2.6×107 PFU vMyx-IL15Rα-tdTr, vMyx-tdTr or PBS. Mice received a second i.t. inoculation of 2.6×107 PFU of each virus on day 10. (A) Growth of individual tumors. Dashed lines designate time of virus treatment, and tumor size was measured every 2 days. (B) Kaplan–Meier survival curve of the same experimental subjects. Numbers next to corresponding survival curves designate median survival time (days). (* - p<0.05 for vMyx-IL15Rα-tdTr treated group compared to PBS).